R
Rita Bellevue
Researcher at New York Methodist Hospital
Publications - 20
Citations - 4360
Rita Bellevue is an academic researcher from New York Methodist Hospital. The author has contributed to research in topics: Sickle cell anemia & Acute chest syndrome. The author has an hindex of 17, co-authored 20 publications receiving 3886 citations. Previous affiliations of Rita Bellevue include Houston Methodist Hospital & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Elliott Vichinsky,Lynne Neumayr,A. Earles,Roger Williams,Evelyne T. Lennette,Deborah Dean,Bruce G. Nickerson,Eugene P. Orringer,Virgil McKie,Rita Bellevue,Charles Daeschner,E A Manci +11 more
TL;DR: A treatment protocol that included matched transfusions, bronchodilators, and bronchoscopy was evaluated and it was found that infection and fat embolism are underdiagnosed in patients with the syndrome.
Journal ArticleDOI
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
Martin H. Steinberg,Martin H. Steinberg,Franca B. Barton,Oswaldo Castro,Charles H. Pegelow,Samir K. Ballas,Abdullah Kutlar,Eugene P. Orringer,Rita Bellevue,Nancy F. Olivieri,James R. Eckman,Mala Varma,G. Ramirez,Brian Adler,Wally R. Smith,Timothy M. Carlos,Kenneth I. Ataga,Laura DeCastro,Carolyn Bigelow,Yogen Saunthararajah,Margaret Telfer,Elliott Vichinsky,Susan Claster,Susan Shurin,Kenneth Bridges,Myron A. Waclawiw,Duane Bonds,Michael L. Terrin +27 more
TL;DR: In a long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine whether hydroxyuraxurea attenuates mortality in Patients With SCA as discussed by the authors.
Journal ArticleDOI
Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.
Frances M. Gill,Lynn A. Sleeper,Steven J. Weiner,Audrey K. Brown,Rita Bellevue,Ranjeet Grover,Charles H. Pegelow,Elliott Vichinsky +7 more
TL;DR: Within the Cooperative Study of Sickle Cell Disease, 694 infants with confirmed sickle cell disease were enrolled at less than 6 months of age and information about the nature and frequency of complications was collected prospectively over a 10-year period.
Journal ArticleDOI
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
Martin H. Steinberg,William F. McCarthy,Oswaldo Castro,Samir K. Ballas,F. Danny Armstrong,Wally R. Smith,Kenneth I. Ataga,Paul Swerdlow,Abdullah Kutlar,Laura DeCastro,Myron A. Waclawiw,Eugene P. Orringer,Susan Jones,D. Strayhorn,Wendell F. Rosse,George Phillips,D. Peace,A. Johnson-Telfair,Lisa Daitch,Paul F. Milner,A. Tracy,S. Valdez,G. E. Allen,J. Moshang,B. Scott,Carolyn Bigelow,A. Anderson,V. Sabahi,T. Harrington,W. Labrousse,Charles H. Pegelow,D. Temple,E. Case,R. Harrell,S. Childerie,Stephen H. Embury,B. Schmidt,D. Davies,Yogen Saunthararajah,Mabel Koshy,N. Talischy-Zahed,L. Dorn,G. Pendarvis,M. McGee,Margaret Telfer,A. Davis,O. C. Onyekwere,C. Nwokolo,Helga Finke,Elliott Perlin,J. Siteman,M. Bryan,T. Saunders,Y. Barber,P. Gascon,P. Di Paolo,S. Gargiulo,James R. Eckman,E. Carter-Randall,J. H. Bailey,A. Platt,L. Waller,G. Ramirez,V. Knors,S. Hernandez,E. M. Rodriguez,E. Wilkes,Elliott Vichinsky,Ward Hagar,C. Hoehner,E. Hackney-Stevens,S. Claster,A. Earles,K. Kleman,K. McLaughlin,L. White,B. Maddox,L. Usry,A. Brenner,K. Williams,R. O'Brien,K. Genther,Susan B. Shurin,Brian W. Berman,K. Chiarucci,L. Keverline,Nancy F. Olivieri,J. Chow,M. Hui,D. Shaw,N. Lewis,Maureen Okam,Elyse Mandell,A. Palmer,Kenneth Bridges,B. Tynan,C. Winograd,Rita Bellevue,Harvey Dosik,M. Sheikhai,P. Ryans,H. Souffrant,Brian Adler,L. Eskridge,Josef T. Prchal,J. Braddock,T. McArdle,Timothy M. Carlos,A. Roundtree-Schmotzer,D. Gardner +109 more
TL;DR: It is suggested that long‐term use of hydroxyurea is safe and might decrease mortality, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment.
Journal ArticleDOI
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Yutaka Niihara,Scott T. Miller,Julie Kanter,Sophie Lanzkron,Wally R. Smith,Lewis L. Hsu,Victor R. Gordeuk,Kusum Viswanathan,Sharada A. Sarnaik,Ifeyinwa Osunkwo,Edouard Guillaume,Swayam Sadanandan,Lance Sieger,Joseph L. Lasky,Eduard H. Panosyan,Osbourne A. Blake,Tamara New,Rita Bellevue,Lan T. Tran,Rafael Razon,Charles W Stark,Lynne Neumayr,Elliott Vichinsky +22 more
TL;DR: Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l‐glutamine, administered alone or with hydroxyurea, than amongThose who received placebo, with or without hydroxyUREa.